Products

Enzymes for Research, Diagnostic and Industrial Use

PF-04457845

Cat No.
CEI-1470
Description
PF-04457845 is a potent and exquisitely selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH) with an IC50 value of 7.2 nM.
Product Overview
Fatty acid amide hydrolase or FAAH is a member of the serine hydrolase family of enzymes. It was first shown to break down anandamide in 1993. PF-04457845 is a potent and exquisitely selective inhibitor of the FAAH, and both analgesic and antiinflammatory effects in animal studies comparable to naproxen. Clinical trial: A clinical trial was approved to evaluate the pharmacology and tolerability of PF-04457845 in healthy subjects. Results showed that FAAH1 activity was almost completely inhibited (>97%) following doses of at least 0.3 mg (single dose) and 0.5 mg once daily (multiple dose) PF-04457845. Mean fatty acid amide concentrations increased (3.5-to 10-fold) to a plateau and then were maintained following PF-04457845. FAAH1 activity and fatty acid amide concentrations returned to baseline within 2 weeks following cessation of dosing at doses up to 4 mg. There was no evidence of effects of PF-04457845 on cognitive function. PF-04457845, at doses up to 40 mg single dose and 8 mg once daily for 14 days, was well tolerated. These data indicated PF-04457845 was well tolerated at doses exceeding those required for maximal inhibition of FAAH1 activity and elevation of fatty acid amides.
CAS No.
1020315-31-4
Molecular Weight
455.43
Purity
0.98
Storage
Store at -20°C
Synonyms
PF 04457845; PF04457845
Targets
FAAH
IC50
7.2 nM
Molecular Formula
C23H20F3N5O2
Chemical Name
N-pyridazin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methylidene]piperidine-1-carboxamide
Solubility
Soluble in DMSO
Shipping Conditions
Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request
In vitro
Mechanistic studies confirm that PF-04457845 is a time-dependent, covalent FAAH inhibitor that carbamylates FAAHs catalytic serine nucleophile. PF-04457845 inhibits human FAAH with high potency and is exquisitely selective in vivo as determined by activity-based protein profiling.
In vivo
Oral administration of PF-04457845 produced potent antinociceptive effects in both inflammatory and noninflammatory pain models in rats, with a minimum effective dose of 0.1 mg/kg. PF-04457845 also displayed a long duration of action as a single oral administration at 1 mg/kg showed in vivo efficacy for 24 h with a concomitant near-complete inhibition of FAAH activity and maximal sustained elevation of anandamide in brain. Significantly, PF-04457845-treated mice at 10 mg/kg elicited no effect in motility, catalepsy, and body temperature. These data suggest PF-04457845 is a clinical candidate for the treatment of pain and other nervous system disorders.
Download Datasheet:



Inquiry
Online Inquiry
Name:
*Phone:
*E-mail Address:
Country:
Company/Institution:
*Products or Services Interested:
Quantity:
Project Description:
Our Products are Not Intended for Private Therapeutic Use!
*Verification Code:
Please input "enzymes"(case insensitive) as verification code.

Welcome! For price inquiries, please feel free to contact us through the form below through the form on the left side. We will get back to you as soon as possible.

Sitemap  Privacy Policy
Copyright ©2011 - 2017 Creative Enzymes.
Contact Us 45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-enzymes.com
Tel: 1-631-562-8517 1-631-448-7888
Fax: 1-631-938-8127
Distributors To view the contact information for a specific location, select the desired country: